Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Recruitment Status

Completed clinical trials

Status pages show live ClinicalTrials.gov search results by recruitment status, with direct links to official study records plus page-level filtering and sorting.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 4:58 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials
121392
Shown on this page
12
Current sort
Recently updated
Status scope
Completed
Additional filters apply within this recruitment status.

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

Filter and sort this status page

These controls apply only within Completed. Default order is Recently updated. Add condition, location, sponsor, or therapy filters to narrow this status page further.

Reset status filters
Clear filters
Showing 277–288 of 121,392 matching trials with status Completed.
Live ClinicalTrials.gov results.
Local aggregate panels are unavailable or hidden for filtered views. The result list above identifies its data source.

Live official records

Open in full search
Completed Phase 2 Interventional Results available

Study of Nab-Paclitaxel and Gemcitabine and Plus/Minus VCN-01 in Patients With Metastatic Pancreatic Cancer

NCT05673811
View directory record Official record
Conditions
Pancreatic Adenocarcinoma, Metastatic
Interventions
Nab-paclitaxel, Gemcitabine, VCN-01
Drug · Genetic
Lead sponsor
Theriva Biologics SL
Industry
Eligibility
18 Years and older
Enrollment
112 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
7
States / cities
Newport Beach, California • Sacramento, California • Louisville, Kentucky + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 30, 2026 · Synced Nov 5, 2026, 4:58 AM EST
Completed Not applicable Interventional

To Evaluate the Preliminary Efficacy of Our Digitally Enhanced CHW-led Intervention in Newly Diagnosed PDAC

NCT07591571
View directory record Official record
Conditions
Pancreatic Cancer, Adult
Interventions
PAL-CHW-PDAC, Usual Care with Attention Control
Behavioral · Other
Lead sponsor
Loma Linda University
Other
Eligibility
18 Months and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Loma Linda, California
Source: ClinicalTrials.gov public record
Updated Oct 30, 2026 · Synced Nov 5, 2026, 4:58 AM EST
Completed Phase 4 Interventional

A Study to Evaluate the Safety and Efficacy of Baricitinib in the Treatment of Frontal Fibrosing Alopecia (FFA)

NCT06240351
View directory record Official record
Conditions
Frontal Fibrosing Alopecia
Interventions
Baricitinib 4 MG Oral Tablet
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years to 90 Years · Female only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Oct 30, 2026 · Synced Nov 5, 2026, 4:58 AM EST
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase 1, Dose-Escalation, Positron Emission Tomography Study to Assess the Safety, Pharmacokinetics, Dosimetry and Biodistribution of GEH200521 (18F) Injection Co-Administered With GEH200520 Injection in Healthy Volunteers

NCT06398730
View directory record Official record
Conditions
Healthy Volunteers
Interventions
GEH200520 Injection and GEH200521 (18F) Injection, Static - PET/CT scan
Drug · Diagnostic Test
Lead sponsor
GE Healthcare
Industry
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Oct 30, 2026 · Synced Nov 5, 2026, 4:58 AM EST
Completed Phase 4 Interventional

A Non-Randomized Open Label Clinical Trial Evaluating DermaBind TL

NCT07172893
View directory record Official record
Conditions
Diabetic Foot Ulcer (DFU), Venous Leg Ulcer (VLU)
Interventions
DermaBind TL
Biological
Lead sponsor
HealthTech Wound Care
Industry
Eligibility
18 Years to 80 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
10
States / cities
DeLand, Florida • Palm Beach Gardens, Florida • Sweetwater, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Oct 30, 2026 · Synced Nov 5, 2026, 4:58 AM EST
Completed Not applicable Interventional

A Safety and Effectiveness Prospective Blinded Clinical Study to Validate xBar System as Monitoring Tool for Anastomotic Leaks Detection

NCT06168669
View directory record Official record
Conditions
Colorectal Surgery, Anastomotic Leak
Interventions
xBar system
Diagnostic Test
Lead sponsor
Exero Medical Ltd.
Industry
Eligibility
22 Years and older
Enrollment
222 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
9
States / cities
Orlando, Florida • Tampa, Florida • Louisville, Kentucky + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 30, 2026 · Synced Nov 5, 2026, 4:58 AM EST
Completed Phase 1Phase 2 Interventional Results available

Clazakizumab in Highly-HLA Sensitized Patients Awaiting Renal Transplant

NCT03380962
View directory record Official record
Conditions
Kidney Failure, Chronic, End-Stage Renal Disease, Transplant Glomerulopathy, Transplant;Failure,Kidney, Kidney Transplant Failure and Rejection, Antibody-mediated Rejection, Kidney Transplant; Complications
Interventions
Clazakizumab
Drug
Lead sponsor
Stanley Jordan, MD
Other
Eligibility
15 Years to 75 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Oct 30, 2026 · Synced Nov 5, 2026, 4:58 AM EST
Completed Phase 2 Interventional Results available

A Study to Assess Efficacy and Safety of LB54640 in Patients With Hypothalamic Obesity

NCT06046443
View directory record Official record
Conditions
Hypothalamic Obesity
Interventions
Bivamelagon, Placebo
Drug
Lead sponsor
Rhythm Pharmaceuticals, Inc.
Industry
Eligibility
12 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
7
States / cities
Aurora, Colorado • Iowa City, Iowa • Boston, Massachusetts + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 30, 2026 · Synced Nov 5, 2026, 4:58 AM EST
Completed Phase 2 Interventional Results available

Single Dose Study of Phentolamine Mesylate Eye Drops in Patients With Severe Night Vision Disturbances

NCT04004507
View directory record Official record
Conditions
Decrease in Night Vision, Disturbance; Vision, Loss
Interventions
Phentolamine Mesylate Ophthalmic Solution 1%, Phentolamine Mesylate Ophthalmic Solution Vehicle (Placebo)
Drug · Other
Lead sponsor
Opus Genetics, Inc
Industry
Eligibility
18 Years to 80 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Lynbrook, New York
Source: ClinicalTrials.gov public record
Updated Oct 30, 2026 · Synced Nov 5, 2026, 4:58 AM EST
Completed Phase 1 Interventional Accepts healthy volunteers

Safety and Immunogenicity Trial of PepGNP-COVID19 Vaccine in Adults

NCT07183709
View directory record Official record
Conditions
COVID-19
Interventions
PepGNP-COVID19, Sterile Water for Injection
Biological · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 64 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
3
States / cities
Birmingham, Alabama • Washington D.C., District of Columbia • Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 30, 2026 · Synced Nov 5, 2026, 4:58 AM EST
Completed Phase 2 Interventional

A Study of Tislelizumab in Combination With Investigational Agents in Participants With Non-Small Cell Lung Cancer

NCT05635708
View directory record Official record
Conditions
Non-small Cell Lung Cancer, Metastatic Non-small Cell Lung Cancer
Interventions
Tislelizumab, BGB-A445, LBL-007, Carboplatin, Cisplatin, pemetrexed, Paclitaxel, Nab paclitaxel, BGB-15025
Drug
Lead sponsor
BeiGene
Industry
Eligibility
18 Years and older
Enrollment
418 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
5
States / cities
Los Angeles, California • Boston, Massachusetts • New York, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 30, 2026 · Synced Nov 5, 2026, 4:58 AM EST
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Safety and Efficacy of Ophthalmic Phentolamine Mesylate to Reverse Pharmacologically Induced Mydriasis

NCT04024891
View directory record Official record
Conditions
Mydriasis, Dilation
Interventions
Phentolamine Mesylate Ophthalmic Solution 1%, Phentolamine Mesylate Ophthalmic Solution Vehicle (Placebo)
Drug · Other
Lead sponsor
Opus Genetics, Inc
Industry
Eligibility
18 Years to 45 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
4
States / cities
Pittsburg, Kansas • Lexington, Kentucky • Athens, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 30, 2026 · Synced Nov 5, 2026, 4:58 AM EST